Regenerx Biopharmaceuticals Inc (RGN) financial statements (2021 and earlier)

Company profile

Business Address 15245 SHADY GROVE ROAD
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0100101
Cash and cash equivalents0100101
Prepaid expense0000000
Total current assets:0100101
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment (0)00000
Other noncurrent assets0000000
Other undisclosed noncurrent assets 0     
Total noncurrent assets:0000000
TOTAL ASSETS:1100101
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities0000000
Accounts payable0000000
Accrued liabilities0000000
Deferred revenue00
Debt00010  
Derivative instruments and hedges, liabilities   1   
Deferred revenue and credits00  
Other undisclosed current liabilities0 0    
Total current liabilities:0002100
Noncurrent Liabilities
Long-term debt and lease obligation01 0111
Long-term debt, excluding current maturities01 0111
Operating lease, liability0 
Liabilities, other than long-term debt22 2662
Deferred revenue and credits2210
Deferred revenue22
Derivative instruments and hedges, liabilities   0451
Other undisclosed noncurrent liabilities1 2    
Total noncurrent liabilities:3322672
Total liabilities:3324773
Stockholders' equity
Stockholders' equity attributable to parent(3)(2)(2)(4)(6)(7)(2)
Common stock0000000
Additional paid in capital106105104100999898
Accumulated deficit(109)(107)(106)(105)(105)(105)(100)
Total stockholders' equity:(3)(2)(2)(4)(6)(7)(2)
TOTAL LIABILITIES AND EQUITY:1100101

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:000000 
Operating expenses(1)(1)(1)(2)(2)(2)(2)
Operating loss:(1)(1)(1)(1)(2)(2)(2)
Nonoperating income (expense)(0)(0)(1)2 00
Investment income, nonoperating00   00
Other nonoperating expense  (1)    
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Income (loss) from continuing operations before equity method investments, income taxes:(2)(2)(2)0(2)(2)(2)
Other undisclosed income from continuing operations before income taxes0000   
Income (loss) from continuing operations before income taxes:(2)(1)(2)0(2)(2)(2)
Income tax expense (benefit)000(0)   
Net income (loss):(1)(1)(2)0(2)(2)(2)
Other undisclosed net income (loss) attributable to parent(0)(0)(0) 2(3)(1)
Net income (loss) attributable to parent:(2)(1)(2)00(5)(3)
Other undisclosed net loss available to common stockholders, basic (0)     
Net income (loss) available to common stockholders, diluted:(2)(1)(2)00(5)(3)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(1)(1)(2)0(2)(2)(2)
Comprehensive income (loss), net of tax, attributable to parent:(1)(1)(2)0(2)(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: